OSE Immunotherapeutics SA banner

OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 4.32 EUR 1.65%
Market Cap: €97m

OSE Immunotherapeutics SA
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OSE Immunotherapeutics SA
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Non-Reccuring Items
-€14k
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Non-Reccuring Items
-€490k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Non-Reccuring Items
€328k
CAGR 3-Years
N/A
CAGR 5-Years
79%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Non-Reccuring Items
-€8.4m
CAGR 3-Years
-844%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
97m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.84 EUR
Undervaluation 45%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Non-Reccuring Items?
Non-Reccuring Items
-14k EUR

Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Non-Reccuring Items amounts to -14k EUR.

What is OSE Immunotherapeutics SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
64%

Over the last year, the Non-Reccuring Items growth was 46%. The average annual Non-Reccuring Items growth rates for OSE Immunotherapeutics SA have been 64% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett